Development Work for DeepView® Systems Continues with Support of Recently Awarded $31.7 Million of Funding from BARDA Reiterates Annual Revenues Guidance DALLAS, May 12, 2026 (GLOBE NEWSWIRE) — Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the first quarter ended March 31, 2026. “Our results for the 2026 first quarter reflected the progress we have made in developing our DeepView® System for burn indication under the base phase of our Project BioShield Contract with BARDA,” said Vincent Capone, Chief Executive Officer of Spectral AI. “The work we have completed under this base phase – which was ongoing in last year’s first quarter – allowed...

– Duchenne (SGT-003): First participant dosed in the Phase 3 IMPACT DUCHENNE clinical trial, receipt of positive opinion on the Company’s Pediatric Investigation Plan from the European Medicines Agency and Orphan drug designation from the European Commission mark important advancements in the program’s global development – – Continued progress achieved across the SGT-003 development program, including dosing of 47 participants in Phase 1/2 INSPIRE DUCHENNE clinical trial, and ongoing engagement with the FDA for guidance on a potential accelerated approval pathway for SGT-003 – – Friedreich’s Ataxia (SGT-212): Second participant dosed in the Phase 1b FALCON clinical trial; SGT-212 has been well tolerated with no serious adverse events observed – – CPVT (SGT-501): Company anticipates dosing the first...

RALEIGH, N.C., May 12, 2026 (GLOBE NEWSWIRE) — Lumexa Imaging (Nasdaq: LMRI), one of the nation’s largest providers of outpatient imaging services, today announced results for the first quarter ended March 31, 2026, and reiterated full year 2026 guidance.  “In Q1, we delivered several meaningful achievements to kick off a year of executing on our strategic priorities,” said Caitlin Zulla, Chief Executive Officer of Lumexa Imaging. “We continued to drive strong growth in same-center advanced imaging volumes and our de novo centers are ramping according to our plans.” “We are also announcing tonight four additional Lumexa Imaging centers including two strategic tuck-in acquisitions plus two de novos. We are well on our way to achieving our stated goal of adding 8-10 de novos to our network of centers this year.” Ms. Zulla continued,...

Proprietary robotically-navigated MAGiC catheter received U.S. FDA approval in January and is now being utilized at multiple sites across the United States as well as Europe Synchrony digital operating room system received U.S. FDA clearance in April and initial orders and shipments are ongoing Definitive agreement to acquire Robocath creates a leading robotic platform, combining complementary technologies to deliver next-generation fully-integrated robotic solutions for the full spectrum of endovascular proceduresST. LOUIS, May 12, 2026 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported business updates and financial results for the first quarter ended March 31, 2026. “Stereotaxis is in one of the most exciting periods...

Total Revenue Growth of 23.7% Year Over Year in the First Quarter Same Store Sales Growth of 5.2% Year Over Year in the First Quarter Opened 9 New Stores in the First Quarter SCOTTSDALE, Ariz., May 12, 2026 (GLOBE NEWSWIRE) — Black Rock Coffee Bar, Inc. (Nasdaq: BRCB) (“Black Rock Coffee Bar” or the “Company”) today announced financial results for the first quarter ended March 31, 2026. First Quarter 2026 HighlightsOpened 9 new stores during the period Total revenue of $55.5 million, up 23.7% compared to the prior year period Same Store Sales Growth(1) increased 5.2% compared to the prior year period Income from operations of $2.7 million compared to $2.3 million in the prior year period. In the first quarter of 2026, income from operations margin was 4.8% Store-Level Profit(2) of $16.4 million as compared to $12.7 million in...

MALVERN, Pa., May 12, 2026 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the first quarter ended March 31, 2026. Recent HighlightsAnnounced strategic board refreshment plan to be effective at the conclusion of the 2026 Annual Meeting on June 9, 2026; Noted the U.S. commercial organization is fully staffed at planned 2026 levels; Delivered revenue of $19.1 million in the first quarter of 2026, representing growth of 3% over the prior year period; Accelerated European revenue growth to 41% over the prior year period, with continued momentum in the U.K. and early expansion into additional European markets; Announced the U.S. commercial launch of OviTex LTR, providing a specialized,...

Utilization Gains Underpin Improving Same-Location RevenueFifth Asset Sale Under Asset Rotation StrategyReduced Leverage with $12.6 Million of PaydownsConference Call Will be Held on May 12, 2026, at 4:30 PM Eastern Time CINCINNATI, May 12, 2026 (GLOBE NEWSWIRE) — Mobile Infrastructure Corporation (Nasdaq: BEEP), (“Mobile”, “Mobile Infrastructure” or the “Company”), the nation’s only publicly traded owner of parking infrastructure, today reported results for the three months ended March 31, 2026. Commenting on the results, Stephanie Hogue, Chief Executive Officer, said, “Our first quarter results reflect solid execution against the initiatives we laid out for 2026. We focused on driving utilization and contract growth while delivering on the first phase of our asset rotation program. Supported by higher residential demand and continued...

Initiated two late-stage clinical trials of LB-102: the pivotal Phase 3 NOVA-2 trial in schizophrenia and the Phase 2 ILLUMINATE-1 trial in bipolar depression  Published results from the Phase 2 NOVA-1 trial of LB-102 in schizophrenia in The Journal of the American Medical Association (JAMA) Psychiatry Expanded pipeline following $100 million private placement with plans to initiate a Phase 2 trial of LB-102 in adjunctive treatment of major depressive disorder (MDD) in early 2027 Cash, cash equivalents, and marketable securities of $365.6 million as of March 31, 2026 expected to fund operations into Q2 2029, through multiple clinical milestones NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) — LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies...

Management Team to Host Conference Call Tomorrow at 8:30 a.m. ET NORWALK, Conn., May 12, 2026 (GLOBE NEWSWIRE) — Reed’s, Inc. (NYSE American: REED) (“Reed’s” or the “Company”), owner of the nation’s leading portfolio of handcrafted, natural ginger beverages, today announced financial results for the three months ended March 31, 2026. Q1 2026 Financial Highlights (vs. Q1 2025):Net sales were $7.1 million compared to $10.0 million. Gross profit was $0.7 million compared to $3.4 million, with gross margin of 10% compared to 34%. Delivery and handling costs were $2.57 per case compared to $3.17 per case. Selling, general and administrative expenses were $5.8 million compared to $3.5 million. Net loss was $6.5 million compared to $2.0 million. EBITDA1 was $(6.2) million compared to $(1.7) million.Neal Cohane, Reed’s interim CEO...

First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected in 3Q 2026  Cash balance of $23.9 million as of March 31, 2026 anticipated to fund operations into 2027, including completion of the dose escalation portion of the ongoing BDC-4182 Phase 1/2 studyREDWOOD CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) — Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2026, and provided a business update. “We are encouraged by what we have seen thus far in patients treated with BDC-4182, a next-generation Boltbody™ ISAC. BDC-4182 has a unique mechanism of action that has the potential to combine the power of ADCs...